Luke Fletcher, MD
Hematology & Oncology · Eugene, ORNPI 1770979098
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $34,725 of the $43,775 with a category attached, or 79.3%. It is spread thinly across 23 manufacturers, the largest accounting for just 18.3%. Among hematology & oncology clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 67 payments — averaging $653.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$8K
- CTI Biopharma Corp.$6K
- Servier Pharmaceuticals LLC$5K
- Genentech, Inc.$5K
- Pharmaessentia USA Corporation$4K
- Astellas Pharma US Inc$2K
- plus $13K from 17 others
Across 47 payments — averaging $42,576 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.4M
- E.r. Squibb & Sons, L.L.C.$486K
- Sumitomo Pharma America, Inc.$53K
- Pharmaessentia USA Corporation$52K
- Servier Bioinnovation$10K
- F. Hoffmann-la Roche AG$2K
- plus $4K from 2 others
What the payments were for
- Consulting fees$34,72579%
- Speaking & faculty fees$5,60713%
- Travel & lodging$3701%
- Food & beverage$3,0737%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 5 | $8,019 |
| CTI Biopharma Corp. | 3 | $6,091 |
| Servier Pharmaceuticals LLC | 6 | $5,320 |
| Genentech, Inc. | 5 | $5,086 |
| Pharmaessentia USA Corporation | 4 | $3,738 |
| Astellas Pharma US Inc | 4 | $2,355 |
| Bristol Myers Squibb | 5 | $2,251 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $2,100 |
| Morphosys, US Inc. | 2 | $1,713 |
| Janssen Scientific Affairs, LLC | 10 | $1,678 |
| AbbVie | 4 | $1,663 |
| Sanofi | 3 | $1,513 |
| E.r. Squibb & Sons, L.L.C. | 3 | $1,206 |
| Taiho Oncology, Inc. | 3 | $355 |
| Stemline Therapeutics Inc. | 1 | $145 |
| Blueprint Medicines Corporation | 1 | $101 |
| Eli Lilly | 1 | $100 |
| AstraZeneca | 1 | $79 |
| Sobi, Inc | 1 | $76 |
| Amgen | 1 | $65 |
| Pfizer | 1 | $50 |
| Genentech USA, Inc. | 1 | $46 |
| Foundation Medicine, Inc. | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$43,775 in reported general payments places this provider in the 90th percentile of 112 hematology & oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 35 | $603,834 |
| Lenalidomide | 44 | $584,733 |
| VenclextaVenetoclax | 30 | $395,252 |
| PomalystPomalidomide | 15 | $332,672 |
| CabometyxCabozantinib S-Malate | 11 | $270,925 |
| BrukinsaZanubrutinib | 17 | $247,999 |
| TagrissoOsimertinib Mesylate | 12 | $197,238 |
| BesremiRopeginterferon Alfa-2b-Njft | 11 | $152,087 |
| ZelborafVemurafenib | 12 | $121,692 |
| Posaconazole | 27 | $24,933 |
| EliquisApixaban | 34 | $24,251 |
| Hydroxyurea | 110 | $2,478 |
| Cefpodoxime Proxetil | 15 | $2,425 |
| Acyclovir | 175 | $2,323 |
| Potassium Chloride | 34 | $1,507 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVenclexta | $1,663 | $395,25230 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $1,206 | $332,67215 claims |
| AstraZenecaTagrisso | $79 | $197,23812 claims |
| Pharmaessentia USA CorporationBesremi | $3,738 | $152,08711 claims |
| PfizerEliquis | $50 | $24,25134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 112 hematology & oncology providers in Oregon.
Other hematology & oncology in Eugene
- Christopher YasenchakEugene$102K
- James ButrynskiEugene$1K
- Matthew LonerganEugene$941
- Brian DrukerPortland$1.9M
- Bo WangCorvallis$251K
- Jay AndersenPortland$196K
- Richard MaziarzPortland$174K
- Tibor KovacsovicsPortland$119K
- Elie TraerPortland$72K
- Jeffrey MenashePortland$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.